Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8004MR)

This product GTTS-WQ8004MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8004MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2410MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ6187MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ15334MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ1514MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ591MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ1452MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ15140MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ11107MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW